Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis

被引：19

作者：

Wong, Yuen Yan ^{[1
,2
]}

Wu, Che-Yuan ^{[1
,2
]}

Yu, Di ^{[1
,2
]}

Kim, Esther ^{[1
]}

Wong, Melissa ^{[1
]}

Elez, Renata ^{[1
]}

Zebarth, Julia ^{[1
]}

Ouk, Michael ^{[2
]}

Tan, Jocelyn ^{[1
]}

Liao, Jiamin ^{[1
]}

Haydarian, Eileen ^{[2
]}

Li, Siming ^{[1
]}

Fang, Yaolu ^{[1
]}

Li, Peihao ^{[1
]}

Pakosh, Maureen ^{[4
]}

Tartaglia, Maria Carmela ^{[5
]}

Masellis, Mario ^{[2
,6
]}

Swardfager, Walter ^{[1
,2
,3
]}

机构：

[1] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada

[2] Sunnybrook Res Inst, Dr Sandra Black Ctr Brain Resilience & Recovery, Hurvitz Brain Sci Program, Toronto, ON, Canada

[3] KITE UHN Toronto Rehabil Inst, Toronto, ON, Canada

[4] UHN Toronto Rehabil Inst, Lib & Informat Serv, Toronto, ON, Canada

[5] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON, Canada

[6] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Neurol, Toronto, ON, Canada

来源：

PARKINSONISM & RELATED DISORDERS | 2022年 / 101卷

基金：

加拿大健康研究院; 加拿大自然科学与工程研究理事会;

关键词：

Lewy body; Dementia; Parkinson's disease; Blood-brain barrier; Blood biomarker; Neurofilament light chain; PLASMA NEUROFILAMENT LIGHT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; COGNITIVE IMPAIRMENT; DIFFERENTIAL-DIAGNOSIS; SOLUBLE TREM2; SERUM-LEVELS; TAU-PROTEIN; P-TAU;

D O I：

10.1016/j.parkreldis.2022.06.004

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Mixed evidence supports blood-brain barrier (BBB) dysfunction in Lewy body spectrum diseases. Methods: We compare biofluid markers in people with idiopathic Parkinson's disease (PD) and people with PD dementia (PDD) and/or dementia with Lewy bodies (DLB), compared with healthy controls (HC). Seven databases were searched up to May 10, 2021. Outcomes included cerebrospinal fluid to blood albumin ratio (Qalb), and concentrations of 7 blood protein markers that also reflect BBB disruption and/or neurodegenerative copathology. We further explore differences between PD patients with and without evidence of dementia. Random-effects models were used to obtain standardized mean differences (SMD) with 95% confidence interval. Results: Of 13,949 unique records, 51 studies were meta-analyzed. Compared to HC, Q(alb) was higher in PD (N-PD/ N-HC = 224/563; SMD = 0.960 [0.227-1.694], p = 0.010; I-2 = 92.2%) and in PDD/DLB (N-PDD/DLB/N-HC = 265/ 670; SMD = 1.126 [0.358-1.893], p < 0.001; I-2 = 78.2%). Blood neurofilament light chain (NfL) was higher in PD (N-PD/N-HC = 1848/1130; SMD = 0.747 [0.442-1.052], p < 0.001; I-2 = 91.9%) and PDD/DLB (N-PDD/DLB/N-HC = 183/469; SMD = 1.051 [0.678-1.423], p = 0.004; I-2 = 92.7%) than in HC. p-tau 181 (N-PD/N-HC = 276/164; SMD = 0.698 [0.149-1.247], p = 0.013; I-2 = 82.7%) was also higher in PD compared to HC. In exploratory analyses, blood NfL was higher in PD without dementia (N-PDND/N-HC = 1005/740; SMD = 0.252 [0.042-0.462], p = 0.018; I-2 = 71.8%) and higher in PDD (N-PDD/N-HC = 100/111; SMD = 0.780 [0.347-1.214], p < 0.001; I2 = 46.7%) compared to HC. Qalb (N-PDD/N-PDND = 63/191; SMD = 0.482 [0.189-0.774], p = 0.010; I-2 <0.001%) and NfL (N-PDD/N-PDND = 100/223; SMD = 0.595 [0.346-0.844], p < 0.001; I-2 = 3.4%) were higher in PDD than in PD without dementia. Conclusions: Biofluid markers suggest BBB disruption and neurodegenerative co-pathology involvement in common Lewy body diseases. Greater evidence of BBB breakdown was seen in Lewy body disease with cognitive impairment.

引用

页码：119 / 128

页数：10

共 96 条

[41] Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes
Lin, Chin-Hsien
Yang, Shieh-Yueh
Horng, Herng-Er
Yang, Che-Chuan
Chieh, Jen-Jie
Chen, Hsin-Hsien
Liu, Bing-Hsien
Chiu, Ming-Jang
[J]. FRONTIERS IN AGING NEUROSCIENCE, 2018, 10
[42] Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control
Lin, Wei-Che
Lu, Cheng-Hsien
Chiu, Pai-Yi
Yang, Shieh-Yueh
[J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2021, 49 (04) : 401 - 409
[43] Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease
Lin, Yung-Shuan
Lee, Wei-Ju
Wang, Shuu-Jiun
Fuh, Jong-Ling
[J]. SCIENTIFIC REPORTS, 2018, 8
[44] Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
Litvan, Irene
Goldman, Jennifer G.
Troester, Alexander I.
Schmand, Ben A.
Weintraub, Daniel
Petersen, Ronald C.
Mollenhauer, Brit
Adler, Charles H.
Marder, Karen
Williams-Gray, Caroline H.
Aarsland, Dag
Kulisevsky, Jaime
Rodriguez-Oroz, Maria C.
Burn, David J.
Barker, Roger A.
Emre, Murat
[J]. MOVEMENT DISORDERS, 2012, 27 (03) : 349 - 356
[45] Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology
Liu, Huei-Chun
Lin, Wei-Che
Chiu, Ming-Jang
Lu, Cheng-Hsien
Lin, Chin-Yi
Yang, Shieh-Yueh
[J]. PLOS ONE, 2020, 15 (06):
[46] Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
Liu, Huei-Chun
Chiu, Ming-Jang
Lin, Chin-Hsien
Yang, Shieh-Yueh
[J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2020, 10 (01) : 46 - 55
[47] Identification and verification of three key genes associated with survival and prognosis of COAD patients via integrated bioinformatics analysis
Liu, Yong
Li, Chao
Dong, Lijin
Chen, Xuewei
Fan, Rong
[J]. BIOSCIENCE REPORTS, 2020, 40
[48] Increased albumin CSF/serum ratio in dementia with Lewy bodies
Llorens, Franc
Schmitz, Matthias
Gloeckner, Sara Friederike
Kaerst, Lisa
Hermann, Peter
Schmidt, Christian
Varges, Daniela
Zerr, Inga
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 358 (1-2) : 398 - 403
[49] Lu CH, 2015, NEUROLOGY, V84, P2247, DOI [10.1212/WNL.0000000000001642, 10.1212/WNL.0000000000001986]
[50] Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease
Ma, Ling-Zhi
Zhang, Can
Wang, Han
Ma, Ya-Hui
Shen, Xue-Ning
Wang, Jian
Tan, Lan
Dong, Qiang
Yu, Jin-Tai
[J]. JOURNAL OF PARKINSONS DISEASE, 2021, 11 (03) : 1117 - 1127

← 1 2 3 4 5 6 7 8 9 10 →